High Endothelial Venule with Concomitant High CD8+Tumor-Infiltrating Lymphocytes Is Associated with a Favorable Prognosis in Resected Gastric Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Soon Auck | - |
dc.contributor.author | Hwang, Hye Won | - |
dc.contributor.author | Kim, Min Kyoon | - |
dc.contributor.author | Lee, Tae Jin | - |
dc.contributor.author | Yim, Kwangil | - |
dc.contributor.author | Won, Hye Sung | - |
dc.contributor.author | Sun, Der Sheng | - |
dc.contributor.author | Kim, Eun Young | - |
dc.contributor.author | Ko, Yoon Ho | - |
dc.date.accessioned | 2023-03-08T13:56:30Z | - |
dc.date.available | 2023-03-08T13:56:30Z | - |
dc.date.issued | 2020-08 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/63328 | - |
dc.description.abstract | CD8+ tumor-infiltrating lymphocytes (TILs) play a major role in antitumor immunity. High endothelial venules (HEVs) are related to diverse immune cells in solid tumors. We analyzed CD8+ and Foxp3+ TILs in combination with HEVs to determine their prognostic role in advanced gastric cancer (AGC). We enrolled 157 patients with AGC in this study. The densities of CD8+ TILs and Foxp3+ TILs were calculated using immunohistochemical staining. HEVs were evaluated by MECA-79 expression. HEVs were identified in 60 (38.2%) cases and was significantly associated with an increased number of CD8+ TILs (p= 0.027) but not of Foxp3+ TILs (p= 0.455) and CD20+ TILs (p= 0.163). A high CD8+/HEV+ level was significantly associated with nodal metastasis (p= 0.048). In survival analysis, patients with high CD8+/HEV+ levels demonstrated the longest overall survival (OS) (p= 0.015). Furthermore, a high CD8+/HEV+ level was an independent prognostic factor in AGC (p= 0.011; hazard ratio (HR) = 0.435; 95% confidence interval (CI) = 0.245-0.837). HEVs were found to play an important role in antitumor immunity associated with CD8+ TILs in AGC. This analysis of HEVs and CD8+ TILs helps stratify patients with AGC and sheds light on tumor immunity. | - |
dc.format.extent | 12 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | High Endothelial Venule with Concomitant High CD8+Tumor-Infiltrating Lymphocytes Is Associated with a Favorable Prognosis in Resected Gastric Cancer | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/jcm9082628 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL MEDICINE, v.9, no.8, pp 1 - 12 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000564623500001 | - |
dc.identifier.scopusid | 2-s2.0-85105480160 | - |
dc.citation.endPage | 12 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1 | - |
dc.citation.title | JOURNAL OF CLINICAL MEDICINE | - |
dc.citation.volume | 9 | - |
dc.type.docType | Article | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | gastric cancer | - |
dc.subject.keywordAuthor | high endothelial venule | - |
dc.subject.keywordAuthor | CD8+tumor-infiltrating lymphocytes | - |
dc.subject.keywordAuthor | prognosis | - |
dc.subject.keywordPlus | REGULATORY T-CELLS | - |
dc.subject.keywordPlus | SOLID TUMORS | - |
dc.subject.keywordPlus | INFILTRATION | - |
dc.subject.keywordPlus | VESSELS | - |
dc.subject.keywordPlus | FOXP3 | - |
dc.subject.keywordPlus | RECRUITMENT | - |
dc.subject.keywordPlus | MEMORY | - |
dc.subject.keywordPlus | HEVS | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.